Adaptive immunity is related to coronary artery disease severity after acute coronary syndrome in subjects with metabolic syndrome

Autor(es)

Izar, Maria C. ^{[1, 2]} ; Fonseca, Henrique A. ^[1] ; Pinheiro, Luiz F. ^[1] ; Monteiro, Carlos M. ^[1] ; Povoa, Rui M. ^[1] ; Monteiro, Andrea M. ^{[3, 2]} ; Figueiredo-Neto, Antonio M. ^[2] ; Gidlund, Magnus A. ^[3] ; Fonseca, Francisco A. ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, Dept Med, Div Cardiol, BR-04039030 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Natl Inst Complex Fluids, Inst Phys, BR-05508 Sao Paulo - Brazil

^[3] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Diabetes & Vascular Disease Research; v. 10, n. 1, p. 32-39, JAN 2013.
• Citações Web of Science: 9

Resumo

Metabolic syndrome (MetS) is an inflammatory state associated with high coronary disease risk. Inflammation and adaptive immunity modulate atherosclerosis and plaque instability. We examined early changes in anti-oxidized low-density lipoprotein (LDL) (anti-oxLDL) autoantibodies (Abs) in patients with MetS after an acute coronary syndrome (ACS). Patients of both genders (n=116) with MetS were prospectively included after an acute myocardial infarction (MI) or hospitalization due to unstable angina. Anti-oxLDL Abs (IgG class) were assayed at baseline, three and six weeks after ACS. The severity of coronary disease was evaluated by the Gensini score. We observed a decrease in anti-oxLDL Abs titers (p<0.002 vs. baseline), mainly in males (p=0.01), in those under 65 y (p=0.03), and in subjects with Gensini score above median (p=0.04). In conclusion, early decrease in circulating anti-oxLDL Abs is associated with coronary disease severity among subjects with MetS. (AU)

• Processo FAPESP: 04/00325-8 - Efeitos pleitropicos precoces do fenofibrato e atorvastatina, isolados ou combinados, apos sindrome coronariana aguda em pacientes com sindrome metabolica.
• Beneficiário: Francisco Antonio Helfenstein Fonseca
• Linha de fomento: Auxílio à Pesquisa - Regular